Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

publication by KaloBios Pharmaceuticals Inc and collaborators shows EphA3 as target for highly selective anticancer therapy


Thursday, 14 Aug 2014 08:00am EDT 

KaloBios Pharmaceuticals Inc:Announces publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels.The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study. 

Related Company News

Company Quote

1.82
0.01 +0.55%
21 Oct 2014